To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.
Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Funding Rounds (5) - $97.16MUpdate
Current Team (5)Update
|Jun 8, 2016||PRNewswire UK All - Fc Protein and Glycoengineered Antibodies Market 2016-2021 & 2026 - The Concept of Engineered Antibodies Is Being Widely Used for Development for Biobetters/Biosimilars - Research and Markets|
|Jun 3, 2016||Bio Portfolio - argenx successfully closes €30 million private placement|
|Oct 3, 2015||lspvc.com - arGEN-X raises €40 million in successful Initial Public Offering on Euronext Brussels|
|May 20, 2015||Bio Portfolio - arGEN-X awarded €1.5 million IWT grant to advance the application of NHance Fc modifications in therapeutic antibodies|
|Jul 8, 2014||Reuters UK - BRIEF-arGEN-X raises 40 mln euros in Euronext IPO|
|Nov 6, 2013||FinSMEs - arGEN-X Raises Additional €5M in Series B Financing Round|
|Dec 1, 2011||FinSMEs - FinSMEs|
|Feb 15, 2010||OnBioVC - arGEN-X, BV: Series A $4.5MbyOnBioVC|
Dr Molewaterplein 50
Rotterdam, Zuid-Holland 3015